Clinical Trial Update: BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update comparing BIP48 (peginterferon alfa-2b 48 kDa) with Pegasys (peginterferon alfa-2a 40 kDa) for chronic hepatitis C in Phase 2/Phase 3 tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BIP48 (Peginterferon alfa-2b (48 kDa pegylated form))
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Conditions: Chronic Hepatitis C | Phase 2, Phase 3 | Status: UNKNOWN